To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT.
about
Use of segmented CT transmission map to avoid metal artifacts in PET images by a PET-CT deviceAdvances in Molecular Imaging Strategies for In Vivo Tracking of Immune CellsOptimisation of whole-body PET/CT scanning protocolsPelvic Congestion Syndrome Initially Detected by Contrast-Enhanced F-18 FDG-PET/CT.Demonstrating Intertumoural Differences in Vascular-Metabolic Phenotype with Dynamic Contrast-Enhanced CT-PETArtefacts of PET/CT imagesConsistent surgeon evaluations of three-dimensional rendering of PET/CT scans of the abdomen of a patient with a ductal pancreatic mass.Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography.Aptamer technology for tracking cells' status & function.Extraperitoneal urinary bladder perforation detected by FDG PET/CT.One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapyColorectal cancer: the role of PET/CT in recurrence.A quantitative comparison of gross tumour volumes delineated on [18F]-FDG PET-CT scan and CECT scan in head and neck cancers.PET/CT in oncology: for which tumours is it the reference standard?PET/CT imaging: what radiologists need to knowWarburg revisited: imaging tumour blood flow and metabolism.Positron emission tomography for staging and assessment of tumor response of hepatic malignancies.Role of dual PET/CT scanning in abdominal malignancies.Communication between radiologists and nuclear medicine physiciansSeeing SPIOs Directly In Vivo with Magnetic Particle Imaging.Prevalence of clinically significant extraosseous findings on unenhanced CT portions of ¹⁸F-fluoride PET/CT bone scans.
P2860
Q24814275-23C8961E-966A-4A8C-9110-56C16F7A1C64Q28076866-EA1EE27A-73E3-403C-96D8-ECBEBE431DE5Q28744472-C079AD46-15C1-42CA-9183-B09609414A3BQ33670086-85A09EE4-F118-45C6-BA93-3141A8395023Q33918475-7C82AB59-4023-4F46-89F5-EF235DB5899EQ34991912-46AAF8C8-5239-432F-87CF-D0FE05E692EAQ35005463-EF74B243-041B-471B-9B95-377B3BFF8A18Q35093775-06FC3E37-416A-4761-B8C9-238E0D547523Q35673895-DA8F81FA-7789-413D-A940-77F8AAF26C83Q35829306-1901DE7F-6E7D-44F7-9515-C23B99F85291Q36194127-129B0BF0-8649-462A-B04E-ED9DA588A87AQ36345331-111774F8-FABA-491F-8403-975E61B2389EQ36879611-D73CDE82-F213-4A93-85F2-25754EE3293BQ36963748-4367BDD0-780F-4259-A6FC-93CF418E3ADEQ36963769-62A373C3-BBA8-47A6-8B19-00EB4F1BA76BQ37129062-B782F66E-9BA4-4487-86DF-6BBA6EA4ED54Q41951499-151F864E-3768-4291-A82B-90073985CDBAQ42099292-DAAF279C-DCB7-4DD4-B2C5-4B38A7731294Q42745826-CFE501D3-6375-498E-8BB1-B4FCDC3E0ED2Q48293364-91615CB3-2705-4B31-B0EE-47FA76406198Q53140691-5834A34E-A5B0-4920-ACFD-D2E9CD187007
P2860
To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
To enhance or not to enhance? ...... dual-modality 18F-FDG PET/CT.
@ast
To enhance or not to enhance? ...... dual-modality 18F-FDG PET/CT.
@en
type
label
To enhance or not to enhance? ...... dual-modality 18F-FDG PET/CT.
@ast
To enhance or not to enhance? ...... dual-modality 18F-FDG PET/CT.
@en
prefLabel
To enhance or not to enhance? ...... dual-modality 18F-FDG PET/CT.
@ast
To enhance or not to enhance? ...... dual-modality 18F-FDG PET/CT.
@en
P2093
P1476
To enhance or not to enhance? ...... n dual-modality 18F-FDG PET/CT
@en
P2093
Gerald Antoch
Jörg F Debatin
Lutz S Freudenberg
Thomas Beyer
P304
P407
P478
45 Suppl 1
P577
2004-01-01T00:00:00Z